Skip to content
Clinical Trials – home
FranceBack to France

Clinical trials in STRASBOURG, Alsace – page 5

990 clinical trials in STRASBOURG, Alsace, France across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
STRASBOURG, Alsace at a glance
990
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

990 trials in STRASBOURG, Alsace

Open in trial search

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Astellas Pharma Global Development Inc.

Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Primary Immune Complex Membranoproliferative Glomerulonephritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Pegcetacoplan
  • Sponsor:Swedish Orphan Biovitrum AB (publ)

A Phase 3 Study of Efimosfermin Alfa to Assess Safety and Tolerability in Adults with F2‑F3 Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Safety and Efficacy of Efimosfermin Alfa in Participants with Biopsy‑Confirmed F2‑ or F3‑Stage Metabolic Dysfunction‑Associated Steatohepatitis (MASH)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Indacaterol Acetate
  • Sponsor:Novartis Pharma AG

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Long‑Term Safety and Efficacy of RO7790121 in Adults with Moderate to Severe Rheumatoid Arthritis: Extension Study

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:RO7790121
  • Sponsor:F. Hoffmann-La Roche AG

Long‑Term Safety and Tolerability of Oral Fesoterodine in Adults with Hallucinations and Delusions Due to Alzheimer’s Disease Psychosis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fesoterodine
  • Sponsor:Maplight Therapeutics Inc.

Asthma

Recruiting

Efficacy and safety of GB-0895 as adjunctive therapy in adults and adolescents with severe uncontrolled asthma (randomized, placebo‑controlled)

Investigational
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Generate Biomedicines Inc.

Iodixanol in Cerebral Angiography for Patients with Unruptured Intracranial Aneurysms

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Iodixanol
  • Sponsor:Les Hopitaux Universitaires De Strasbourg
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:2-Isopropyl-3H-Naphtho(1,2-D)Imidazole-4,5-Dione
  • Sponsor:Pharming Technologies B.V.

Docetaxel and Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Have a Deep PSA Response After Initial Apalutamide Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in STRASBOURG, Alsace

What the registry says about research in the country

01 Oncology Research

Advanced studies focusing on head and neck cancers, bladder cancer, and multiple myeloma. Novel therapeutic approaches combining immunotherapy with established treatments are being evaluated for improved patient outcomes.

  • EGFR-targeted therapies for head and neck cancer
  • Non-muscle invasive bladder cancer treatment
  • Multiple myeloma consolidation therapy

Innovative combination therapies are being tested to enhance treatment efficacy while maintaining patient safety.

02 Neurological Disorders

Comprehensive research into multiple sclerosis, essential tremor, and ADHD. Studies are evaluating both new and existing medications for improved symptom management and disease control.

  • Multiple sclerosis treatment strategies
  • Essential tremor therapeutic interventions
  • ADHD neural mechanism studies

Advanced neuroimaging techniques are being utilized to understand treatment effects on brain circuits.

03 Autoimmune Conditions

Investigating new treatments for Crohn's disease, Sjögren's Syndrome, and Myasthenia Gravis. Research focuses on innovative therapeutic approaches including microbiota transplantation and targeted immunotherapies.

  • Fecal microbiota transplantation studies
  • Novel antibody treatments
  • Immunomodulatory therapies

These trials aim to improve disease management and patient quality of life through targeted interventions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.